A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion
Status:
Recruiting
Trial end date:
2022-05-29
Target enrollment:
Participant gender:
Summary
The primary objective is to determine if BIIB093 reduces brain contusion expansion by Hour 96
when compared to placebo.
The secondary objectives are to evaluate the effects of BIIB093 on acute neurologic status,
functional outcomes, and treatment requirements, to further differentiate the mechanism of
action of BIIB093 on contusion expansion by examining differential effects on hematoma and
edema expansion, and to determine if BIIB093 improves survival at Day 90 when compared to
placebo.